View Older Stories View More Recent Stories
-
Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial
-
Citius Pharmaceuticals (CTXR) Receives CRL for LYMPHIR
-
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Re
-
Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes
-
Citius Pharmaceuticals (CTXR) Reports Positive Results from the Phase 2b Study of Halo-Lido
-
Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids
-
Citius Pharmaceuticals to Participate in Maxim Group's Virtual Healthcare Conference on June 21, 2023
-
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update
-
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
-
Citius Pharmaceuticals (CTXR) Announces 12.5M Share Offering at $1.20/sh
-
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
-
Citius Pharmaceuticals (CTXR) Advances Mino-Lok Phase 3 Trial Achieving 85 of 92 Events to Date
-
Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date
-
Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
-
Citius Pharmaceuticals (CTXR) Advances Efforts to Spin Off I/ONTAK into Standalone Company
-
Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company
-
Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank
-
Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference
-
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update
-
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023
-
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update
-
Citius Pharmaceuticals (CTXR) Announces FDA Acceptance of BLA of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent C
-
Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program
-
Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (A
-
Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022
-
Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022
-
Citius Pharmaceuticals (CTXR) Submits BLA to FDA for Denileukin Diftitox
-
Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous
-
Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Meta
-
Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute
-
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update
-
Citius Pharmaceuticals (CTXR) Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals (CTXR) Reiterated at Buy by Dawson James on I/ONTAK Spinoff, $10 Price Target Maintained
-
Citius Pharmaceuticals (CTXR) to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company
-
Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company
-
Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022
-
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update
-
Citius Pharmaceuticals (CTXR) to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally
-
Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally
-
Citius Pharmaceuticals (CTXR) Provides Business Update, Highlights Upcoming Milestones
-
Citius Pharmaceuticals, Inc. Provides Business Update, Highlights Upcoming Milestones
-
Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
-
Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022
-
Citius Pharmaceuticals (CTXR) Announces Key Management Realignment to Support Commercialization of Two Late-Stage Product Candidates
-
Citius Pharmaceuticals Announces Key Management Realignment to Support Commercialization of Two Late-Stage Product Candidates
-
Citius Pharmaceuticals (CTXR) Reports Topline Data from Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK for Treatment of CTCL in Support of BLA Submission
